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However, there are several key points 
that emanate from this interesting report. 
These findings serve as an important 
extension of the concept of immunoed-
iting in tumor surveillance (Shankaran 
et al., 2001), and the importance of NK 
cells in shaping the phenotypic charac-
teristics of tumors. These data corrobo-
rate and support previous findings on the 
role of STAT1 in NK cell function, and in 
regulation of MHC class I expression. It 
seems likely, based on these data, that 
there will be functions of STAT1 that are 
both dependent and independent of type 
I IFN signaling, an arena that should be 
of considerable interest for further investi-
gation. These experiments also elegantly 
demonstrate the value of modeling cancer 
in vivo in murine models of disease, and 
the importance of in vivo experimentation 
to dissect out the evolutionary “winner” in 
cell-autonomous tumor-promoting activ-
ity, in apposition to cell-nonautonomous 
host immune response—in this case each 
attributable to deficiency of the same 
allele, STAT1. Finally, this report dem-
onstrates an expanding paradigm that 
some gene products may serve both as 
tumor suppressors and as tumor promot-
ers. Ultimately, clear insights into these 
pathogenetic processes should inform 
more effective therapeutic approaches to 
cancer.
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With the proliferation of high-throughput technologies to profile the cancer genome, methods to distinguish causal from 
bystander genetic events are needed. Two recent reports by Zender et al. and Kim et al. in Cell use genetically defined mouse 
models to serve as biological filters to mine the human cancer genome. Integration of high-resolution copy number profiles 
of mouse tumor models and human tumors identified cIAP1 and Yap as oncogenes in human hepatocellular carcinoma, while 
NEDD9 was identified as a metastasis gene in human melanoma. Together, these reports demonstrate that a comparative 
oncogenomics approach can identify genes causally involved in oncogenesis and metastasis.High-throughput techniques are identify-
ing remarkable heterogeneity in the can-
cer genome, implying that dysregulation 
of numerous genes and pathways can 
lead to oncogenesis and cancer progres-
sion. Furthermore, as cancers progress, 
they demonstrate genomic instability, 
leading not only to the acquisition of muta-
tions conferring selective advantages, but 
also to noncontributing bystander lesions. 
With plans to characterize all mutations 
in human cancers, such as The Cancer 
Genome Atlas (Bonetta, 2005), novel 
techniques to identify the lesions driving 
oncogenesis/metastasis from secondary 
mutations are urgently needed. Two stud-
ies by Zender et al. (2006) and Kim et al. 
(2006) in the June 30 issue of Cell dem-
onstrate the usefulness of comparative 
oncogenomic approaches using defined 
mouse models to identify driving genes 	in oncogenesis and metastasis in human 
tumors (Figure 1).
Comparative oncogenomics identi-
fies cIAP1 and Yap as driving onco-
genes in hepatocellular carcinoma
In the study by Zender et al., the authors 
isolated hepatoblasts from the liver of 
p53−/− mice and overexpressed Myc, acti-
vated Akt, or oncogenic Ras before rein-
troducing these cells into recipient mice 
livers. They focused on tumors develop-
ing from p53−/−;myc-induced hepatoblasts, 
which were histologically consistent with 
human hepatocellular carcinomas (HCCs). 
In an effort to identify spontaneously 
acquired lesions contributing to tumori-
genesis, they used a form of array com-
parative genomic hybridization (aCGH) 
termed representational oligonucleotide 
microarray analysis (ROMA) to search 
for focal regions of copy number change. By ROMA, four of seven Myc-driven HCCs 
contained a focal amplicon (containing 12 
genes) on chromosome 9qA1.
Using the mouse model as a biological 
filter, the authors interrogated 48 human 
HCCs profiled in parallel. Intriguingly, two 
of these human HCCs harbored focal 
amplifications on chromosome 11q22 
(syntenic to mouse 9qA1). To identify the 
driving gene, the authors determined the 
expression of all overlapping genes from 
the syntenic amplicons. Not one, but two 
genes, cIAP1 and Yap, showed increased 
expression at the mRNA and protein level 
in all mouse and human tumors contain-
ing the amplicon.
To confirm the oncogenic effects of 
cIAP1 and Yap in vivo, the authors overex-
pressed these two genes in the p53−/−;myc 
hepatoblasts that were used to generate 
the tumors. Expression of cIAP1 or Yap cancer cell July	006
	 p r e v i e w saccelerated tumor formation and 
increased tumor burden. Similarly, 
knockdown of cIAP1 or Yap in 
tumors containing the 9qA1 ampli-
con inhibited tumor growth. Finally, 
the authors demonstrated that 
cIAP1 and Yap act synergistically 
in the 9qA1 amplicon, as coexpres-
sion of cIAP1 and Yap accelerated 
tumor growth more than expres-
sion of either gene alone.
Comparative oncogenomics 
identifies NEDD9 as a mediator 
of metastasis in melanoma
Kim et al. employed a similar 
approach, using an inducible Ras 
model of nonmetastatic melanoma 
to generate “escapers,” or clones 
that underwent secondary genomic 
events conferring metastatic capa-
bility. The authors characterized two 
such escapers with increased pro-
liferation and invasion compared 
to the parental tumors and profiled 
these samples using genome-wide 
aCGH. Both escapers showed 
a focal amplification on mouse 
chromosome 13, and the overlap-
ping region contained eight genes. 
Examining the expression of these 
eight genes in Ras- and Met-driven 
melanomas, NEDD9 was the only 
gene with increased expression in 
samples with and without genomic 
amplification.
The authors used this result to 
guide the examination of a data-
base of human aCGH profiles 
from melanocytic lesions, where 
chromosome 6p25-24 (syntenic to 
mouse chromosome 13) was found 
to be amplified in 36% of metastat-
ic melanomas, 8% of melanomas, 
and none of the benign nevi. They 
confirmed the overexpression of 
NEDD9 at the transcript and protein 
levels in 35%–52% of metastatic 
melanomas using quantitative RT-
PCR and immunohistochemistry on 
tissue microarrays. To confirm the 
role of NEDD9 in the development 
of metastasis in their escapers, 
the authors knocked down NEDD9 
expression, significantly inhibiting 
the proliferation and invasion of 
the two escapers. Additionally, the 
authors demonstrated that overex-
pression of NEDD9 increased the 
in vitro and in vivo metastatic capa-
bility of primary melanocytes and 
nonmetastatic melanoma cells. cancer cell July	006	Figure 1.	 Biological	 filtering	 using	 defined	 mouse	 models	 to	
identify	driving	mutations	controlling	oncogenesis/metastasis	in	
human	tumors
Schematic	of	the	experimental	approach	used	by	Zender	et	al.	
and	Kim	et	al.	 to	 identify	genes	 involved	 in	 tumor	 initiation	or	
metastasis.	Defined	mouse	models	of	tumorigenesis/metastasis	
were	chosen	 to	mimic	 the	 initiation	or	progression	of	hepato-
cellular	carcinoma	or	melanoma,	respectively.	Isolated	tumors	
from	these	models	were	profiled	by	array	comparative	genomic	
hybridization	(aCGH)-based	techniques	to	identify	focal	regions	
of	copy	number	change.	These	profiles	were	then	used	to	filter	
aCGH	data	from	human	tumors	to	identify	minimally	conserved	
amplified	regions	between	the	mouse	and	human	tumors.	The	
expression	of	all	genes	in	the	amplified	regions	in	both	the	mouse	
models	and	human	tumor	samples	was	determined.	Candidate	
gene(s)	were	chosen	by	increased	expression	in	all	mouse	and	
human	samples	with	the	amplification.	Importantly,	both	groups	
were	then	able	to	confirm	the	effect	of	their	candidate	gene(s)	
in	vitro	or	in	vivo	in	the	same	defined	genetic	model	by	retroviral-
mediated	overexpression	or	shRNA	knockdown.Finally, the authors showed that 
NEDD9 expression induced the 
activation of FAK, a key regulator of 
focal adhesion contacts, and dem-
onstrated that NEDD9 modulates 
the formation of focal contacts in 
melanocytes, suggesting a mecha-
nism for its effects on invasion and 
metastasis.
Advantages and limitations 
of mouse models to identify 
 driving cancer genes
An important aspect of both studies 
was the use of mouse models with 
defined genetic backgrounds. This 
provides the proper genetic back-
ground to confirm the oncogenic/
metastatic effects of identified can-
didate genes, as these effects may 
only occur in cooperation with the 
lesions used to generate the tumor 
models. For example, Zender et 
al. demonstrated that cIAP1 and 
Yap overexpression did not affect 
tumor formation in p53−/−;Akt or 
Ras hepatoblasts. Likewise, Kim 
et al. showed that NEDD9 was 
unable to increase invasion or 
metastasis in melanocytes in the 
absence of activated Ras or Raf. 
Unfortunately, for many tumor 
types, the initiating genetic events 
driving tumorigenesis and the pre-
cursor cells harboring such events 
are unclear, precluding the devel-
opment of such defined models. In 
addition, the experimental strate-
gies utilized by Zender et al. and 
Kim et al., which were designed to 
identify focal amplifications driv-
ing oncogenesis and metastasis, 
would not be able to identify driv-
ing mutations or chromosomal 
rearrangements.
Integrative approaches to 
 identify genes causally 
involved in cancer
Another important result observed 
by both Zender et al. and Kim et al. 
was that the oncogenic amplifica-
tions that they observed in human 
tumors were relatively rare. For 
example, Zender et al. observed 
amplification of the cIAP1 and Yap 
loci in only 2 of 48 (4%) human 
hepatocellular carcinomas, while 
Kim et al. observed amplification 
of the region harboring NEDD9 in 
36% of metastatic melanomas. 
These results likely reflect the 
substantial genetic heterogene-
	 p r e v i e w sity that underlies tumorigenesis and the 
development of metastasis. Recently, our 
group developed a bioinformatics strate-
gy termed Cancer Outlier Profile Analysis 
(COPA) in an effort to identify “oncogene 
outliers,” or genes with marked overex-
pression in a fraction of cases, which 
characterize genes involved in high-level 
copy number changes or translocations, 
such as those described above. COPA 
identified the Ets transcription factors 
ERG and ETV1 as outliers across mul-
tiple prostate cancer profiling studies. 
Characterizing cases with overexpres-
sion of ERG or ETV1, we demonstrated 
that these samples harbored recurrent 
gene fusions with the androgen-regulat-
ed gene TMPRSS2, and these fusions 
occur in the majority of prostate cancers 
(Tomlins et al., 2005). This approach was 
useful in the analysis of tumors without 
biologically relevant mouse models and 
may prove useful in mining mouse mod-
els of cancer as well.
In addition to using mouse models 
or bioinformatic strategies, other groups 
have used alternative integrative analy-
ses to identify driving genetic events in 
tumorigenesis. For example, Garraway et 
al. performed an integrative analysis com-
bining gene expression and copy number 
profiles of the NCI60 panel of cancer cell 
lines to identify and validate MITF as a 
lineage-specific oncogene amplified in a 	
In contrast to normal cells, cancer cells 
have a high glycolytic rate and produce 
high levels of lactate even in the pres-
ence of oxygen (Figure 1). This metabolic 
shift to a higher rate of aerobic glycolysis 
is commonly referred to as the Warburg 
effect. Because glycolysis produces ener-
gy (ATP) far less efficiently than aerobic 
Differential utilization 
is regulated by p53
A fundamental property of cancer cells i
Renewed interest in understanding the m
understanding of the relationship betwee
tumor suppressor regulates the expressio
a multimeric protein complex required for
tion is compromised in cells that lack funsubset of melanomas (Garraway et al., 
2005). Adler et al. also integrated expres-
sion and copy number profiles from breast 
cancers to identify coordinated amplifica-
tion of Myc and CSN5 as a regulator of the 
wound response profile that is predictive 
of poor outcome (Adler et al., 2006).
Amassing genomic scale data for 
human tumors is becoming relatively 
routine. The rapid advancement of 
high-throughput techniques suggests 
that complete genomic profiles of 
tumor samples may soon be realized. 
Integrative approaches will be needed to 
sift through this mass of data to identify 
the driving genetic lesions underlying 
cancer development and progression. 
The results of Zender et al. and Kim et al. 
demonstrate that integrative approaches 
based on defined mouse models can 
be used as one such method to identify 
driving oncogenic or metastatic events 
in human tumors.
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metabolism. A commonly held view is that 
constitutive upregulation of glycolysis is 
likely to be an adaptation to hypoxia that 
develops as tumor cells grow progres-
sively further away from their blood supply 
(Gatenby and Gillies, 2004). Interestingly, 
cells derived from tumors continue to uti-
lize glycolysis in culture under normoxic 
athways  
ver aerobic respiration to produce ATP. 
 in energy production is broadening our 
t article, Matoba et al. report that the p53 
assembly of cytochrome c oxidase (COX), 
 of these findings is that aerobic respira-
